TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19753737
Drug: Dexpanthenol-containing cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexpanthenol-containing cream
Study: 8529437
Drug: Twice-a-day combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-a-day combined administration
Study: 2028709
Drug: Cytidine 5'-diphosphocholine
Normalized name: Cytidine 5'-diphosphocholine
DrugBank: Citicoline (DB12153)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytidine 5'-diphosphocholine (2 g iv infusion)
Study: 6987042
Drug: Cephradine given
Normalized name: Cephradine
DrugBank: Cefradine (DB01333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cephradine given twice daily (70 patients)
Study: 6987042
Drug: Cephradine given
Normalized name: Cephradine
DrugBank: Cefradine (DB01333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cephradine given four times daily (61 patients)
Study: 27883295
Drug: ABCC5 rs939339A>G
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABCC5 rs939339A>G
Study: 25125580
Drug: PF‐05105679 (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF‐05105679 (600 mg)
Study: 25125580
Drug: PF‐05105679 (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF‐05105679 (900 mg)
Study: 25125580
Drug: Oxycodone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone (20 mg)
Study: 18928997
Drug: Antioxidant supplementation
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplementation (vitamin C 1000 mg and vitamin E 400 IU)
Study: 2491361
Drug: Cimetidine, 800
Normalized name: Cimetidine, 800 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine, 800 mg once daily
Study: 21550950
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir at 50% of intravenous basal insulin requirements
Study: 21550950
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir at 65% of intravenous basal insulin requirements
Study: 21550950
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir at 80% of intravenous basal insulin requirements
Study: 18807247
Drug: Delta(9)‐THC (0.0286
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delta(9)‐THC (0.0286 mg/kg)
Study: 11298545
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (ALA-PDT)
Study: 30336808
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of granisetron (1 mg tablet, twice daily every 12 hours for 5 days)
Study: 30336808
Drug: Transdermal delivery
Normalized name: nitroglycerin 5 mg in 1 d TRANSDERMAL PATCH [Nitroglycerin Transdermal Delivery System]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal delivery of granisetron (34.3 mg/52 cm2 patch for 6 days)
Study: 21660397
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (zinc acetate syrup)
Study: 21660397
Drug: Placebo (vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (vitamin B-complex syrup)
Study: 17213598
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: 7.5 mg bupivacaine + 5 microg sufentanil + 10% glucose
Study: 17213598
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: 7.5 mg bupivacaine + 7.5 microg sufentanil + 10% glucose
Study: 17213598
Drug: Group C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C: 15 mg bupivacaine + 10% glucose
Study: 11818299
Drug: Control condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control condition (non-drug-related television program)
Study: 10430716
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (20 ppm delivered during inspiration)
Study: 10430716
Drug: Norepinephrine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine + Inhaled NO
Study: 10430716
Drug: Almitrine bismesylate
Normalized name: almitrine dimesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrine bismesylate + Inhaled NO
Study: 10430716
Drug: Almitrine bismesylate
Normalized name: almitrine dimesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrine bismesylate + Norepinephrine + Inhaled NO
Study: 2144835
Drug: Nicotinamide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotinamide (100 mg/year of age up to a maximum of 1.5 g/day)
Study: 6996121
Drug: Luteinizing hormone‐releasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luteinizing hormone‐releasing hormone (LH‐RH) 500 micrograms 8‐hourly
Study: 6361311
Drug: Long-acting cephalexin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting cephalexin granules (L-CEX)
Study: 30286416
Drug: Ketamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.5 mg/kg over 45 minutes)
Study: 27431306
Drug: Daily nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily nasal saline irrigation supported by a demonstration video
Study: 27431306
Drug: Daily steam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily steam inhalation
Study: 27431306
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with both interventions
Study: 22040532
Drug: SABA purchased
Approvals — FDA: no, EMA: no, PMDA: no
Description: SABA purchased with prescription
Study: 22040532
Drug: SABA purchased
Approvals — FDA: no, EMA: no, PMDA: no
Description: SABA purchased without prescription
Study: 22040532
Drug: Anti‐inflammatory asthma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti‐inflammatory asthma medication
Study: 16285996
Drug: Triflusal 300
Normalized name: triflusal 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triflusal 300 mg/day
Study: 16285996
Drug: Triflusal 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triflusal 600 mg/day
Study: 16285996
Drug: Triflusal 900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triflusal 900 mg/day
Study: 10414671
Drug: Clonidine (3‐4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (3‐4 mcg/kg)
Study: 489767
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg indoprofen
Study: 6776161
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg indoprofen
Study: 17149760
Drug: chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: chemotherapy with simultaneous weekly trastuzumab for 24 weeks (n = 29)
Study: 17149760
Drug: both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: both treatment regimens
Study: 15233841
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of resistance and all-round, functional training
Study: 2154047
Drug: Proton beam
Normalized name: Beam
DrugBank: Tricyclazole (DB02891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton beam treatment
Study: 30391389
Drug: High-dose heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose heparin (100 IU/kg body weight administered in divided doses)
Study: 30391389
Drug: Standard-dose heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose heparin (50 IU/kg body weight)
Study: 30391389
Drug: High-dose heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose heparin (100 IU/kg body weight)
Study: 25671951
Drug: Bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection of 30 mg/kg tranexamic acid
Study: 25671951
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of tranexamic acid
Study: 22742439
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy for insomnia (CBTI); details on dosage and duration not specified.
Study: 15894479
Drug: Inhaled HFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled HFA beclomethasone (Ventolair)
Study: 12515670
Drug: rhGH small
Normalized name: rhGH
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH small dose (0.3 IU.kg(‐1).d(‐1))
Study: 12515670
Drug: rhGH large
Normalized name: rhGH
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH large dose (0.6 IU.kg(‐1).d(‐1))
Study: 9488531
Drug: Glutamine dipeptide-enriched
Normalized name: Alanyl-glutamine dipeptide
DrugBank: Alanyl glutamine (DB11876)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamine dipeptide-enriched total parenteral nutrition (TPN)
Study: 9488531
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (1.5 g of amino acids kg(‐1) day(‐1))
Study: 7999488
Drug: Midazolam 0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.06 mg kg‐1 i.m.
Study: 7999488
Drug: Diazepam 0.2
Normalized name: diazepam 0.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 0.2 mg kg‐1 orally
Study: 26436473
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of intravenous acetaminophen every 6 hours until ICU discharge, resolution of fever, cessation of antimicrobial therapy, or death
Study: 26436473
Drug: Placebo every
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo every 6 hours until ICU discharge, resolution of fever, cessation of antimicrobial therapy, or death
Study: 16343858
Drug: Teicoplanin 800
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin 800 mg pre-operatively (Group A)
Study: 16343858
Drug: Teicoplanin 400
Normalized name: Teicoplanin 400 mg powder for solution for injection vial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin 400 mg pre-operatively plus two doses of 200 mg 24 h apart (Group B)
Study: 12544006
Drug: Red wine
Normalized name: Red wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red wine (40 g of alcohol daily for 3 weeks)
Study: 12544006
Drug: Beer (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beer (40 g of alcohol daily for 3 weeks)
Study: 12544006
Drug: Spirits (Dutch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirits (Dutch gin) (40 g of alcohol daily for 3 weeks)
Study: 8726169
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (other anti-platelet drugs and/or warfarin potassium)
Study: 2874411
Drug: Postoperative adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative adjuvant chemotherapy with cyclophosphamide, methotrexate, and fluorouracil (CMF)
Study: 24035369
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional treatment (control)
Study: 2874411
Drug: Postoperative adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative adjuvant chemotherapy with CMF
Study: 25948674
Drug: Topical saffron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical saffron (Crocus sativus L) gel
Study: 23620937
Drug: Acupuncture at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture at Sifeng (EX-UE 10), treatment given once a week for 4 weeks.
Study: 23620937
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group with erkangning syrup, administered 3 times a day for 4 weeks.
Study: 25562712
Drug: Oxandrolone (Ox)
Normalized name: Oxandrolone
DrugBank: Oxandrolone (DB00621)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxandrolone (Ox) 0.03 mg/kg/day
Study: 25562712
Drug: Oxandrolone (Ox)
Normalized name: Oxandrolone
DrugBank: Oxandrolone (DB00621)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxandrolone (Ox) 0.06 mg/kg/day
Study: 20814189
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone + Oxandrolone (Ox) / Placebo (Pl)
Study: 18360665
Drug: FRILJET local
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: FRILJET local cryoanesthesia and pulp vitality test agent
Study: 12920470
Drug: Intravaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravaginal misoprostol (25 g every 4 hours, not exceeding 8 doses)
Study: 12920470
Drug: Intravenous oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous oxytocin (continuous infusion)
Study: 7939948
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg mebendazole (locally produced)
Study: 7939948
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg mebendazole (original)
Study: 7939948
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg mebendazole (original)
Study: 7939948
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg albendazole (original)
Study: 27611039
Drug: 25 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 μg dexmedetomidine
Study: 27611039
Drug: 50 μg
Normalized name: penicillin G 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 μg dexmedetomidine
Study: 27611039
Drug: 75 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 μg dexmedetomidine
Study: 25555183
Drug: 8-week stress
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8-week stress management program (10 min diaphragmatic breathing and 15 min progressive muscle relaxation twice per day)
Study: 20693886
Drug: C1‐esterase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: C1‐esterase inhibitor (100 U/kg)
Study: 18842789
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg quercetin
Study: 18842789
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg (‐)‐epicatechin
Study: 18842789
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg epigallocatechin gallate
Study: 8768870
Drug: GH/IGF‐I treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH/IGF‐I treatment (0.34 mg GH twice daily and 5.0 mg IGF‐I twice daily)
Study: 8768870
Drug: GH/IGF‐I treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH/IGF‐I treatment
Study: 3908494
Drug: Metronidazole (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (250 mg, 1 tablet 3 times per day for 5 days)
Study: 31486700
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg of fluvastatin daily for 6 weeks
Study: 27990769
Drug: Brushing from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brushing from the buccal aspect
Study: 27016644
Drug: ENG implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: ENG implant
Study: 22971985
Drug: Occupational Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational Therapy (OT) - cooking activities once a week for 15 weeks
Study: 20462664
Drug: 45 mg
Normalized name: lutein 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 mg of ustekinumab
Study: 20462664
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg of ustekinumab
Study: 18573392
Drug: High-dose insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose insulin therapy (5 mU/kg/min) with dextrose 20% to maintain blood glucose levels between 70 and 110 mg/dL (group II)
Study: 18573392
Drug: Intraoperative intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative intravenous insulin infusion, titrated to maintain blood glucose concentrations less than 180 mg/dL (group I)
Study: 16143197
Drug: Latanoprost intratympanic
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Latanoprost intratympanic injection (once daily for 3 days)
Study: 16143197
Drug: Placebo intratympanic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intratympanic injection
Study: 10618936
Drug: Intra-articular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular morphine 1 mg
Study: 10618936
Drug: Intra-articular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular morphine 4 mg
Study: 6406705
Drug: Amino acids
Normalized name: Amino acids
DrugBank: Amino acids (DB09393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acids alone (1.4 g/kg/day)
Study: 6406705
Drug: Amino acids
Normalized name: Amino acids
DrugBank: Amino acids (DB09393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acids (1.4 g/kg/day) plus 5% dextrose
Study: 27102812
Drug: blended Cognitive
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: blended Cognitive Behavioural Therapy (bCBT) combining face-to-face and online sessions over 19-20 weeks
Study: 27102812
Drug: blended Cognitive
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: blended Cognitive Behavioural Therapy (bCBT)
Study: 24399768
Drug: Puerh tea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Puerh tea extract capsule (333 mg Puerh tea extract) three times a day
Study: 21073130
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (primary conventional treatment alone)
Study: 17668232
Drug: 5,000 IU
Normalized name: bleopmycin 15,000 IU Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5,000 IU rHuEpo every second day for 14 days, followed by a single dose of 5,000 IU weekly for 10 weeks
Study: 9813955
Drug: Methylphenidate (fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (fixed dose for at least 1 month)
Study: 8106759
Drug: Intranasal live
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal live cold-adapted (ca) influenza A vaccine
Study: 8106759
Drug: Intramuscular trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular trivalent inactivated (triv) influenza vaccine
Study: 1131627
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of primidone and phenytoin
Study: 31059418
Drug: 9 months
Normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 9 months of twice‐weekly isoniazid (9H)
Study: 31059418
Drug: 12 once‐weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 once‐weekly doses of isoniazid and rifapentine (3HP)
Study: 28733656
Drug: Glucocorticoid and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoid and cyclophosphamide (50-100 mg per day)
Study: 28733656
Drug: Prednisone monotherapy
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone monotherapy (0.5-1.0 mg/kg.d, tapered gradually)
Study: 21742284
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil applied to abdominal skin area twice a day until the end of the study term
Study: 16884439
Drug: Selective serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin reuptake inhibitors (SSRI) treatment for 12 weeks
Study: 11402106
Drug: Interferon beta-1a,
Normalized name: INTERFERON BETA-1A,RECOMBINANT
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon beta-1a, 44 microg three times weekly for 3 years
Study: 11402106
Drug: Interferon beta-1a,
Normalized name: INTERFERON BETA-1A,RECOMBINANT
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon beta-1a, 22 microg three times weekly for 3 years
Study: 9230722
Drug: Inhaled formoterol
Normalized name: formoterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled formoterol (FM) 24 micrograms twice daily for 4 weeks
Study: 9230722
Drug: Inhaled formoterol
Normalized name: formoterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled formoterol (FM) + oral prednisolone 50 mg
Study: 9230722
Drug: Inhaled formoterol
Normalized name: formoterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled formoterol (FM)
Study: 9230722
Drug: Inhaled formoterol
Normalized name: formoterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled formoterol (FM) + systemic corticosteroid
Study: 8501271
Drug: 0.5% delmopinol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% delmopinol HCl (aqueous solution)
Study: 2945499
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg loratadine
Study: 2945499
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg loratadine
Study: 2960701
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg descarboethoxyloratadine
Study: 2960701
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg descarboethoxyloratadine
Study: 2960701
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg descarboethoxyloratadine
Study: 19959537
Drug: Very low
Normalized name: Very low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very low cerebral blood volume (VLCBV) with a cutpoint at 2 mL and <2.5th percentile threshold
Study: 14510091
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose povidone-iodine
Study: 10768517
Drug: Cefepime +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime + Metronidazole (2 g cefepime + 500 mg metronidazole)
Study: 10768517
Drug: Ceftriaxone +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone + Metronidazole (2 g ceftriaxone + 500 mg metronidazole)
Study: 8777468
Drug: ANF (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANF (all doses)
Study: 1325989
Drug: Prostaglandin-F2 alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostaglandin-F2 alpha instillation into the solitary tube and systemic prostaglandin administration
Study: 1325989
Drug: Prostaglandin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostaglandin treatment for tubal pregnancy
Study: 6664677
Drug: 1% betaxolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% betaxolol ophthalmic solution
Study: 30669763
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose group (100 kV + ASIR)